Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing trial and cohort literature without formal systematic search methodology.
PubMed 41889156 · doi:10.1111/dom.70713
What was done
The authors conducted a narrative review synthesizing evidence from randomized withdrawal trials (including STEP-1 extension, STEP-4, and SURMOUNT-4), systematic reviews, meta-analyses, and real-world observational cohorts encompassing over 289,000 patients to evaluate metabolic trajectories, mechanisms, and clinical outcomes following GLP-1 receptor agonist discontinuation.
What was found
GLP-1 receptor agonist discontinuation was associated with a 60% to 90% regain of lost weight within one year and a reversal of cardiometabolic benefits. Modeling studies indicated that glycemic, blood pressure, and lipid parameters returned to baseline within approximately 12 months, and HbA1c normalized within 12 to 18 months. Early discontinuation (< 1 year) was associated with higher risks of coronary artery disease and heart failure compared with continued treatment.
Why it matters
These findings emphasize that GLP-1 receptor agonist cessation triggers biological adaptations that rapidly erode cardiometabolic improvements, framing discontinuation as a high-risk clinical event requiring structured multidisciplinary management rather than a routine endpoint.
Limits
As a narrative review, the study is subject to selection bias and lacks pooled quantitative effect estimates or formal meta-analytic quality assessments. The abstract does not provide exact effect sizes or confidence intervals for heart failure or coronary disease risks, and validated tapering strategies remain absent.
Cited by
- context Tapering down the dose of GLP-1 drugs helps slow weight regain compared to stopping all at once.